ADAM metallopeptidase domain 19 (ADAM19)

ADAM metallopeptidase domain 19 (ADAM19) is a type I transmembrane enzyme belonging to the ADAM (A Disintegrin and Metalloproteinase) family, characterized by its multi-domain structure that includes a metalloproteinase, disintegrin, cysteine-rich, epidermal growth factor-like, transmembrane, and cytoplasmic regions[1][2][4]. ADAM19 is expressed in various tissues and regulates diverse biological processes such as cell adhesion, migration, and extracellular matrix remodeling, primarily through ectodomain shedding of membrane-bound proteins (including cytokines like TNF-α)[1][2][4]. It plays essential roles in embryogenesis, cardiac development, neurogenesis, immune cell maturation, and has been implicated in the pathogenesis of metabolic syndrome, cancer, tissue fibrosis, inflammation, and neurodegeneration[1][2][3][4]. ADAM19 is a therapeutic target under investigation, particularly in metabolic diseases and inflammatory disorders; experimental strategies include neutralizing antibodies, siRNA knockdown, and broad-spectrum metalloprotease inhibitors like Batimastat (BB-94), though selective inhibitors for ADAM19 are not yet clinically available[1][3].

Other names

Disintegrin and metalloproteinase domain-containing protein 19Meltrin-betaMADDAMMLTNBFKSG34Metalloprotease and disintegrin dendritic antigen markermetalloprotease-disintegrin meltrin beta

Metalloproteinase inhibition (blocks substrate cleavage and ectodomain shedding), Antibody-mediated neutralization (blocks enzymatic activity), siRNA knockdown (reduces gene expression)